Pharmaceutical giant AstraZeneca (NYSE:AZN) inked a deal with Owlstone Medical to use the diagnostics company’s breath biopsy device to identify biomarkers for asthma and chronic obstructive pulmonary disease, the companies announced today.
Owlstone’s ReCiva breath sampler, which has CE Mark clearance in the E.U., captures volatile organic compounds in a patient’s breath. A VOC profile can be used to non-invasively diagnose disease at a very early stage and monitor treatment response, according to Owlstone.
AstraZeneca and Owlstone hope to identify disease phenotypes of COPD and asthma to better target effective treatments to the right groups of patients, the companies said.
“This agreement with AstraZeneca demonstrates our unrivalled expertise in breath biomarkers. Through our breath biopsy services we are well positioned to assist the AstraZeneca team to explore how breath biopsy can identify novel biomarkers for asthma and COPD and to optimize their application in precision medicine,” Owlstone co-founder & CEO Billy Boyle said in prepared remarks.
AstraZeneca isn’t the only pharma player that Owlstone has partnered with; in November last year, the company announced that GlaxoSmithKline (NYSE:GSK) planned to use the breath biopsy system in a phase II trial of its COPD drug, danirixin.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.